Aduro Biotech (ADRO) closed the most recent trading day at $3.33, moving -0.6% from the previous trading session.
Aduro Biotech (ADRO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aduro Biotech (ADRO) delivered earnings and revenue surprises of 18.18% and 58.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is (ADRO) Outperforming Other Medical Stocks This Year?
Aduro Biotech (ADRO) closed the most recent trading day at $2.54, moving +1.2% from the previous trading session.
Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is (ADRO) Outperforming Other Medical Stocks This Year?
As you might know, Aduro Biotech, Inc. (NASDAQ:ADRO) just kicked off its latest quarterly results with some very...
Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.
Is (ADRO) Outperforming Other Medical Stocks This Year?
Aduro Biotech (ADRO) delivered earnings and revenue surprises of 18.18% and 58.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BERKELEY, Calif., May 04, 2020 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
Aduro Biotech, Inc. (NASDAQ:ADRO) shareholders will have a reason to smile today, with the analysts making substantial...
BERKELEY, Calif., March 09, 2020 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
Aduro BioTech, Inc. (NASDAQ:ADRO) shareholders will doubtless be very grateful to see the share price up 146% in the...
Is (ADRO) Outperforming Other Medical Stocks This Year?
Aduro Biotech (ADRO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BERKELEY, Calif. (AP) — Aduro Biotech Inc. (ADRO) on Monday reported a loss of $7.6 million in its first quarter.
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -14.29% and -26.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host a live conference call and webcast on Monday, June 8, 2020 at 1:00 pm PDT to report data in healthy volunteers from the ongoing Phase 1 study of BION-1301 for the treatment of IgA nephropathy (IgAN) as well as data from long-term nonclinical studies. Members of the Aduro executive team will be joined by Dr. Jonathan Barratt, the Mayer Professor of Renal Medicine at University of Leicester.
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BERKELEY, Calif., Feb. 24, 2020 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is.
As of late, it has definitely been a great time to be an investor in Aduro Biotech.